Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension
Journal of Alzheimer’s Disease · 2026
DOI: 10.1177/13872877251401601 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Alzheimer’s Disease, 2026. Verfasst von Yu Nakamura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, Kagawa, Japan. Hauptthemen laut MEDLINE: Rivastigmine, Alzheimer Disease, Transdermal Patch, Cholinesterase Inhibitors. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Towa Pharmaceutical Co., Ltd.
Themen: Demenz
Abstract (Originalsprache)
Background
Rivastigmine may offer greater efficacy and convenience of use with a novel formulation than previously reported.
Objective
To evaluate the efficacy and safety of a novel, twice-weekly rivastigmine patch (TW-4752N) (TW) in Alzheimer's disease (AD) patients with mild to moderate dementia.
Methods
This was a multicenter, phase III, double-blind study comparing TW and an existing rivastigmine transdermal patch (RT) with an open-label extension. The primary endpoint was the change in ADAS-Jcog total score at week 24 from baseline. Secondary endpoints included the ADAS-Jcog total score at weeks 8, 16, and 24.
Results
A total of 354 and 362 patients were available for efficacy and safety analysis, respectively. Changes in ADAS-Jcog total score at week 24 from baseline were similar between the two groups in the full analysis set with an intergroup difference of −0.84 ± 0.44 (95% CI, −1.695 to 0.016) and with the upper limit of the 95% CI being below the non-inferiority margin of 1.1, demonstrating the non-inferiority of TW. However, analysis of the per-protocol set demonstrated a significant intergroup difference in favor of TW likely suggesting a greater treatment effect with TW than with RT (p = 0.032). Adverse events (AEs) reported in ≥3% of patients were similar between the groups, with the only AE with an intergroup difference of ≥10% in incidence being application site pruritus (TW/RT, 27.6%/17.1%).
Conclusions
TW represents a viable alternative option of interest to patients with AD, providing comparable or potentially greater efficacy than RT and comparable safety, as well as greater convenience of use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, Kagawa, Japan.
- Clinical Development Department, Pharmaceutical Development Unit, R&D Division, Towa Pharmaceutical Co., Ltd, Osaka, Japan.
ORCID-Profile: Takaya Kurokawa
Förderung
- Towa Pharmaceutical Co., Ltd
Zitieren
APA
Nakamura, Y., Kurokawa, T., Terashima, S., & Nishimura, A. (2026). Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251401601
Vancouver
Nakamura Y, Kurokawa T, Terashima S, Nishimura A. Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877251401601
BibTeX
@article{Nakamura2026,
author = {Nakamura, Yu and Kurokawa, Takaya and Terashima, Shun and Nishimura, Akira},
title = {Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877251401601}
}
EUVIMED